Related Experiment Videos
Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo
Luigi Leanza1, Matteo Romio2, Katrin Anne Becker3
1Department of Biology, University of Padova, viale G. Colombo 3, 35121 Padova, Italy.
Abstract:
The potassium channel Kv1.3 is highly expressed in the mitochondria of various cancerous cells. Here we show that direct inhibition of Kv1.3 using two mitochondria-targeted inhibitors alters mitochondrial function and leads to reactive oxygen species (ROS)-mediated death of even chemoresistant cells independently of p53 status. These inhibitors killed 98% of ex vivo primary chronic B-lymphocytic leukemia tumor cells while sparing healthy B cells. In orthotopic mouse models of melanoma and pancreatic ductal adenocarcinoma, the compounds reduced tumor size by more than 90% and 60%, respectively, while sparing immune and cardiac functions. Our work provides direct evidence that specific pharmacological targeting of a mitochondrial potassium channel can lead to ROS-mediated selective apoptosis of cancer cells in vivo, without causing significant side effects.
Insights
Targeting the mitochondrial potassium channel Kv1.3 with novel inhibitors selectively kills cancer cells, including chemoresistant types, via reactive oxygen species (ROS)-mediated apoptosis, sparing healthy cells and showing significant tumor reduction in vivo.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The potassium channel Kv1.3 is upregulated in cancer cell mitochondria.
- Mitochondrial Kv1.3 is a potential target for cancer therapy.
Purpose of the Study:
- To investigate the efficacy of mitochondria-targeted Kv1.3 inhibitors in cancer treatment.
- To determine if Kv1.3 inhibition induces cancer cell death independently of p53 status.
Main Methods:
- Utilized two novel mitochondria-targeted Kv1.3 inhibitors.
- Assessed effects on mitochondrial function and reactive oxygen species (ROS) production.
- Tested ex vivo on chronic B-lymphocytic leukemia cells and in vivo on melanoma and pancreatic ductal adenocarcinoma mouse models.
Main Results:
- Inhibitors induced ROS-mediated cancer cell death, including chemoresistant cells.
- Ex vivo, 98% of chronic B-lymphocytic leukemia cells were killed, sparing healthy B cells.
- In vivo, tumor size was reduced by >90% (melanoma) and >60% (pancreatic cancer), with preserved immune and cardiac functions.
Conclusions:
- Pharmacological targeting of mitochondrial Kv1.3 is a viable strategy for selective cancer apoptosis.
- Mitochondrial Kv1.3 inhibition offers a promising therapeutic approach with minimal side effects.